NASDAQ:IDXX - IDEXX Laboratories Stock Price, News, & Analysis

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its Board of Directors has authorized a stock buyback program on Sunday, June 4th 2017, which authorizes the company to buyback 3,000,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings results on Wednesday, August, 1st. The company reported $1.23 EPS for the quarter, beating the Zacks' consensus estimate of $1.17 by $0.06. The company had revenue of $580.75 million for the quarter, compared to analyst estimates of $574.68 million. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. The company's revenue for the quarter was up 14.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share (EPS) guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus estimate of $4.15. The company issued revenue guidance of $2.205-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

6 analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their forecasts range from $215.00 to $260.00. On average, they expect IDEXX Laboratories' stock price to reach $238.00 in the next year. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT) and Vermillion (VRML).

News articles about IDXX stock have trended somewhat positive recently, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave media stories about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for IDEXX Laboratories.

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.25%), Fundsmith Equity Fund L.P. (5.12%), Renaissance Technologies LLC (2.51%), Bank of New York Mellon Corp (1.28%), Bank of New York Mellon Corp (1.28%) and Northern Trust Corp (1.19%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael Lane, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Columbus Circle Investors, Wells Fargo & Company MN, Bank of America Corp DE, Janus Henderson Group PLC, FMR LLC, Federated Investors Inc. PA and TCW Group Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Michael Lane and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was acquired by a variety of institutional investors in the last quarter, including Fundsmith Equity Fund L.P., Marshall Wace LLP, Ardevora Asset Management LLP, Worldquant Millennium Quantitative Strategies LLC, CIBC Private Wealth Group LLC, First Trust Advisors LP, Renaissance Technologies LLC and Baird Financial Group Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $243.00.

IDEXX Laboratories has a market capitalization of $20.86 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]